Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | G6PD | P11413 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146466 | 1.00 | KMT2A (0.68) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL9311985 | 0.86 | KMT2A (0.75) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL29531243 | 0.86 | MAPK1 (0.50) | KMT2AMEN1HPGDHTTALDH1A1 | |
| SCHEMBL1939816 | 0.86 | MAPK1 (0.50) | KMT2AMEN1HPGDHTTALDH1A1 | |
| SCHEMBL4010958 | 0.85 | MEN1 (0.77) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL11451542 | 0.84 | MEN1 (0.54) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL8635787 | 0.83 | GABRP (0.57) | KMT2AMEN1HPGDHTTCYP1A2 | |
| SCHEMBL6072206 | 0.82 | KMT2A (0.70) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL1272337 | 0.82 | KMT2A (0.70) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL4210079 | 0.82 | LMNA (0.64) | KMT2AHPGDALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189289-A1 | INHIBITORS OF EPHB3 SIGNALING | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-117003744-A | Five-membered and six-membered compound, intermediate, preparation method, composition and application | 厦门市博瑞来医药科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-110734417-B | 2-butenolide acetamide compound and preparation method and application thereof | 南开大学 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022187612-A1 | INHIBITORS OF EPHB3 SIGNALING | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-108276323-B | 3-functionalized N (O, S) -heteroandene derivatives and application thereof in respiratory syncytial virus resistance | 北京交通大学 | 2020-12-29 | — | — | CN | disclosed |
| CN-110734417-A | 2-butenolide acetamide compound and preparation method and application thereof | 南开大学 | 2020-01-31 | — | — | CN | disclosed |
| EP-3210469-A1 | USE OF SUBSTITUTED THIO-1,2,4-TRIAZOLES FOR INCREASING STRESS TOLERANCE IN PLANTS | Bayer Cropscience AG (DE) | 2017-08-30 | — | — | EP | disclosed |
| CN-107108579-A | It is used for the derovatives of 5 [(base of piperazine 1) 3 oxopropyls] imidazolidine 2,4 for treating osteoarthritis as ADAMTS inhibitor | 加拉帕戈斯股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1286967-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001087838-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0507417-B1 | Process for the selective reduction of the 4-halogen in 2,4-dihaloanilines | DOWELANCO (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0507417-A2 | Process for the selective reduction of the 4-halogen in 2,4-dihaloanilines | DOWELANCO (US) | 1992-10-07 | — | — | EP | disclosed |
| US-5089653-A | Having amine-protecting groups, such as diacetanilide or succinimide; palladium catalyst; hydrolyzing to deprotect | DOW ELANCO (US) | 1992-02-18 | — | — | US | disclosed |
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | KMT2A 3236/4885MEN1 3147/4885NPC1 325/4885 |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | CACNA1C, CACNA1D, CACNA1G | KMT2A 3232/4885MEN1 4056/4885NPC1 2407/4885 |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | KMT2A 2954/4885MEN1 3255/4885NPC1 2968/4885 |
| US-20240189289-A1 | INHIBITORS OF EPHB3 SIGNALING | EPHB3, EPHB1, EPHB2 | KMT2A 1704/4885MEN1 2938/4885NPC1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.